As a leader in the Canadian life science investment community, Lumira Ventures has been closely monitoring and engaging with companies who are developing COVID-19 treatments and vaccines. While our portfolio companies and employees within have been significantly impacted by the …
Trending at Lumira Ventures
Lumira Ventures continues Double Bottom Line Challenge to provide support to those in need during the COVID-19 crisis.
This week, Lumira Ventures is proud to have supported five additional high impact COVID-19 initiatives as part of our Double Bottom Line Challenge While some provinces and states are gradually beginning to reopen, unfortunately the magnitude and reach of the …
IMV Announces Proposed $22.3 Million Private Placement
DARTMOUTH, Nova Scotia–(BUSINESS WIRE)– IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company, today announced its intention to complete a private placement (the “Private Placement”) of 7,797,203 units of the Company (each, a “Unit”) at the market price of …
Lumira Ventures launches the Double Bottom Line Challenge to provide support to those in need during the COVID-19 crisis.
At Lumira Ventures, the past couple of months have been consumed with evaluating new investment opportunities, and working with our portfolio companies, governments, and the venture and healthcare ecosystems to ensure that our companies and all innovation-centric companies broadly are …
Edesa Biotech and Light chain Bioscience Sign License Agreement to Develop Treatments for COVID-19 Pneumonia and Other Disorders
TORONTO, ON / ACCESSWIRE / April 20, 2020 / Edesa Biotech, Inc. (EDSA), a clinical-stage biopharmaceutical company, today announced a strategic agreement with Light Chain Bioscience (a brand of NovImmune SA), a leading Swiss pharmaceutical development company, for an exclusive worldwide …
Edwards Lifesciences announces exclusive right to acquire Corvia Medical, Inc.
IRVINE, Calif., — Edwards Lifesciences Corporation EW, -0.99% the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced two strategic transactions involving companies with structural heart disease technologies. Edwards has invested $35 million in …
Aurinia Receives Notice of Allowance from the US Patent and Trademark Office for Claims Directed to Its Novel Voclosporin Dosing Protocol for Lupus Nephritis
Allowed claims cover an individualized flat-dosed pharmacodynamic treatment protocol utilized in the AURA-LV study and the ongoing AURORA study in lupus nephritis Claims have the potential to protect voclosporin’s method of use and dosing protocol for LN until December 2037 …
Aurinia Announces Voclosporin Ophthalmic Solution Demonstrates Statistically Superior Efficacy Versus Restasis® in a Phase 2 Head-to-Head Study for the Treatment of Dry Eye Syndrome
VOS showed statistical superiority to Restasis® on FDA-accepted objective signs of DES 42.9% of VOS subjects vs 18.4% of Restasis® subjects (p=.0055) demonstrated ≥ 10mm improvement in STT at Week 4 Primary endpoint of drop discomfort at 1-minute on Day …
Investigational New Drug (IND)-Submission Milestone Achieved in Lilly Collaboration
VANCOUVER, British Columbia — Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional therapeutics, today reported the achievement of a new development milestone in its collaboration with Eli Lilly and Company (“Lilly”). In accordance with Zymeworks’ 2014 licensing and …
Cardiac Dimensions Appoints Carmelo Mastrandrea as Vice President of Sales
Medical Device Industry Expert to Spearhead European Sales of the Carillon Mitral Contour System KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Dimensions®, a leader in the development of innovative, minimally invasive treatment modalities to address heart failure and related cardiovascular conditions, today announced the appointment …
KalGene Appoints James E. Callaway, Ph.D. as Chief Executive Officer
Veteran Life Sciences Executive Brings Proven Experience Developing CNS Therapeutics MONTREAL and TORONTO, Jan. 4, 2019 /CNW/ – KalGene Pharmaceuticals Inc., a biotechnology company developing therapeutics to slow the progression of Alzheimer’s disease, today announced the appointment of James Callaway, …
Endotronix Hires Industry Veteran Jim Yearick as Senior Vice President of Sales and Marketing
LISLE, Ill., Jan. 3, 2019 – Endotronix, Inc., a digital health and medical technology company dedicated to advancing the treatment of heart failure, today announced that industry veteran Jim Yearick has joined the executive leadership team as Senior Vice President …
Engage Therapeutics Successfully Completes Open Label Portion of Phase 2b StATES Study and Begins Enrollment in Double-Blind Placebo-Controlled Portion
Trial evaluating safety and efficacy of Staccato Alprazolam in subjects with epilepsy and a predictable seizure pattern Results from the open label portion of the study will be presented at a major medical meeting in 2019 NEW ORLEANS, Dec. 03, …
Antios Therapeutics Raises $25 Million in Oversubscribed Series A Financing to Pursue Hepatitis B Cure
International Group of Investors from Canada, the U.S. and China Support Former Senior Executives from Pharmasset and Idenix in New Venture ATLANTA, Nov. 27, 2018 /PRNewswire/ — Antios Therapeutics, Inc. (“Antios”) today announced the completion of a US$25 million oversubscribed …
Exact Imaging Wins 2019 “Life Science Company of the Year” from Life Science Ontario (LSO)
Exact Imaging’s Novel ExactVu™ Micro-Ultrasound System is Helping Urologists Worldwide Revolutionize Prostate Cancer Detection TORONTO, Nov. 22, 2018 /PRNewswire/ – Exact Imaging, the world’s leader in high-resolution micro-ultrasound systems enabling real-time imaging and biopsy guidance for the prostate, proudly announces this it has …